659 related articles for article (PubMed ID: 4615541)
21. Horizons in tumor immunology. A seminar.
Wilson RE; Alexander P; Rosenberg SA; Simmons RL
Arch Surg; 1974 Jul; 109(1):17-29. PubMed ID: 4834133
[No Abstract] [Full Text] [Related]
22. BCG in cancer therapy: theoretical bases of immunotherapy.
Dodd MJ
Am J Nurs; 1979 Feb; 79(2):310-4. PubMed ID: 311587
[No Abstract] [Full Text] [Related]
23. The cell-mediated immunity in patients with malignant melanoma.
Fixa B; Komárková O; Kraus Z; Simková H
Neoplasma; 1978; 25(3):353-7. PubMed ID: 683378
[TBL] [Abstract][Full Text] [Related]
24. [Development in the immunotherapy of malignant melanoma].
Tritsch H
Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
[TBL] [Abstract][Full Text] [Related]
25. [Evidence for tumor immunity in human malignant melanoma].
Nagel GA
Schweiz Med Wochenschr; 1970 Jun; 100(23):995-1000. PubMed ID: 4947017
[No Abstract] [Full Text] [Related]
26. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
27. In vitro testing in tumor immunotherapy.
Berkelhammer J
Semin Oncol; 1974 Dec; 1(4):397-408. PubMed ID: 4143489
[No Abstract] [Full Text] [Related]
28. Cell-mediated immunity against malignant melanoma in monozygous twins.
Nagel GA; St Arneault G; Holland JF; Kirkpatrick D; Kirkpatrick R
Cancer Res; 1970 Jun; 30(6):1828-32. PubMed ID: 5466283
[No Abstract] [Full Text] [Related]
29. [Cellular and genetic aspects of antibody formation (author's transl)].
Sado T
Tanpakushitsu Kakusan Koso; 1975 Jul; 20(9):833-43. PubMed ID: 1103236
[No Abstract] [Full Text] [Related]
30. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
Seigler HF; Shingleton WW; Pickrell KL
Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
[TBL] [Abstract][Full Text] [Related]
31. [Immunological conditions in patients with malignant melanoma of the skin].
Kristensen E
Ugeskr Laeger; 1976 Feb; 138(8):463-8. PubMed ID: 1258214
[No Abstract] [Full Text] [Related]
32. [Current aspects of melanoma research. I. Classification, immunology].
Wätzig V
Dermatol Monatsschr; 1977 May; 163(5):353-8. PubMed ID: 301834
[No Abstract] [Full Text] [Related]
33. Effects on cancer patients of leukapheresis with the continuous-flow blood cell separator. II. Immunologic parameters in vitro.
Waldman SR; Roth JA; Kern DH; Pilch YH
J Lab Clin Med; 1975 Dec; 86(6):950-61. PubMed ID: 127818
[TBL] [Abstract][Full Text] [Related]
34. [The state of transplantation immunology from an experimental viewpoint].
von Broen B
Z Exp Chir; 1975; 8(4):198-214. PubMed ID: 162019
[No Abstract] [Full Text] [Related]
35. Specific T cell-dependent, antigen-antibody mediated suppression of macrophages: abrogation by nonspecifically stimulated T cells.
Rao VS; Mokyr MB; Gershon RK; Mitchell MS
J Immunol; 1977 Jun; 118(6):2117-24. PubMed ID: 325141
[No Abstract] [Full Text] [Related]
36. Cell interactions in antibody formation.
Bell RG
J Am Vet Med Assoc; 1982 Nov; 181(10):1011-14. PubMed ID: 6184351
[No Abstract] [Full Text] [Related]
37. Immunology and immunotherapy of human malignant melanoma.
Bystryn JC
Dermatol Clin; 1985 Apr; 3(2):327-34. PubMed ID: 2937585
[TBL] [Abstract][Full Text] [Related]
38. Workshop in human tumor immunology.
Oettgen HF; Bean MA; Klein G
Cancer Res; 1972 Dec; 32(12):2845-53. PubMed ID: 4345410
[No Abstract] [Full Text] [Related]
39. Immunology and cutaneous malignant melanoma.
Sober AJ
Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
[No Abstract] [Full Text] [Related]
40. Melanoma and immunity.
Rheins LA; Nordlund JJ
Immunol Ser; 1989; 46():769-87. PubMed ID: 2484957
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
